After capturing the North American market with Wegovy (semaglutide) and Zepbound (tirzepatide), Novo Nordisk A/S and Eli Lilly and Co. are advancing blockbuster glucagon-like peptide-1 (GLP-1) ...

Product Categories ...

Biopharma and med-tech company deals and M&As: Abbott, Alvotech, Ambros, Amplitude, Avricore, Beyond Air, Bioarctic, BMS, Chai Discovery, Chong Kun Dang, Darmiyan ...

Despite Vertex Pharmaceuticals Inc.’s mostly positive phase III study results of a non-opioid for treating moderate to severe acute pain, the data for a key secondary endpoint show VX-548 is not as ...

Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have disclosed sodium channel protein type 8 subunit α (SCN8A; Nav1.6) blockers reported to be useful for the ...

Gilead Sciences Inc. has exercised its option to obtain an exclusive license for a preclinical bispecific program under its 2022 collaboration agreement with Macrogenics Inc., triggering a $10 million ...

Mother’s Pharmaceutical Co. Ltd. has discovered high affinity nerve growth factor receptor (NTRK1; TRKA) allosteric inhibitors potentially useful for the treatment of diabetic neuropathy, neuropathic ...

Xilio Therapeutics Inc. has announced in its quarterly earnings report that it has received IND clearance from the FDA for XTX-501, a bispecific PD-1 / masked IL-2 with potential as a foundational ...

Remedium Bio Inc. has announced the initial closing of its planned $10 million series A financing as it advances its durable protein therapeutics platform toward first-in-human development.

Infinimmune Inc. raised $75 million in a series A round, co-led by Regeneron Ventures and Playground Global, to advance its IL-22-targeted IFX-101 and IL-13-targeted IFX-201 into the clinic in 2027 ...

Spyre Therapeutics Inc. has announced the launch of SPY-772, a new combination program comprising SPY-072, a long-acting anti-TL1A antibody, and SPY-007, a novel long-acting anti-IL-17A/F antibody in ...

Acurx Pharmaceuticals Inc. has established a new scientific partnership with Leiden University Medical Center to advance development of Acurx’s DNA polymerase IIIC (pol IIIC) inhibitor antibiotics.